Biovica, Eisai sign agreement to analyze DiviTum for improved cancer drug assessment in animal models

NewsGuard 100/100 Score

Biovica and Eisai Inc. have entered into a lab services agreement to analyze DiviTum™, an assay measuring serum thymidine kinase, for improved drug evaluation in animal cancer models.

In a preclinical setting at Eisai’s Andover innovative Medicine’s (AiM) Institute, Biovica’s non-invasive DiviTum™ technology will be used to test for evidence of tumor growth rate and correlation to tumor volume change. The objective is to investigate DiviTum™ as a tool for early evidence of drug efficacy that later can be transferred to be studied in humans and clinical studies, since DiviTum™ is able to measure enzymes strongly connected with the DNA-synthesis and cell proliferation rate.

“We look forward to working with Eisai, a company which develops important cancer drugs and has a substantial oncology pipeline. In this project we want to demonstrate the preclinical utility and unique information that DiviTum™ can provide to pharmaceutical companies developing novel oncology drugs,” said Biovica CEO Anders Rylander. “This aligns with our strategy to present DiviTum™ as a valuable tool in the early setting, in order to provide data that may be of great use in future clinical development and for the benefit of cancer patients.”

Eisai’s AiM Institute is a dedicated R&D innovation unit in Andover, Mass., which consists of 90 scientists focused delivering novel targeted medicines, discovered and validated by human genetics and related sources to patients. To learn more about Eisai AiM, please visit

“This work will allow us to examine whether DiviTum™ can give us early signals of efficacy in blood collected from our pre-clinical animal models. If successful, this information could support future development of targeted medicines and translate into clinical utility,” said Mark Matijevic, Associate Director, Translational Biomedicine, Eisai AiM Institute.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DASH diet may lower the risk of cardiovascular disease in breast cancer survivors